Enlivex Therapeutics Ownership
| ENLV Stock | USD 1.05 0.04 3.67% |
Shares in Circulation | First Issued 2013-06-30 | Previous Quarter 19.5 M | Current Value 21.3 M | Avarage Shares Outstanding 7.4 M | Quarterly Volatility 8.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Enlivex |
Enlivex Stock Ownership Analysis
About 22.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.93. Some equities with similar Price to Book (P/B) outperform the market in the long run. Enlivex Therapeutics recorded a loss per share of 0.98. The entity last dividend was issued on the 6th of March 2019. The firm had 1:8 split on the 6th of March 2019. Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel. Enlivex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 71 people. To learn more about Enlivex Therapeutics call the company at 972 2 670 8072 or check out https://www.enlivex.com.Besides selling stocks to institutional investors, Enlivex Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Enlivex Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Enlivex Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Enlivex Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 6.0% of Enlivex Therapeutics are currently held by insiders. Unlike Enlivex Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Enlivex Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Enlivex Therapeutics' insider trades
Enlivex Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Enlivex Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enlivex Therapeutics backward and forwards among themselves. Enlivex Therapeutics' institutional investor refers to the entity that pools money to purchase Enlivex Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2024-12-31 | 9.2 K | Signaturefd, Llc | 2024-12-31 | 5 K | Simplex Trading, Llc | 2024-12-31 | 3.4 K | Jpmorgan Chase & Co | 2024-12-31 | 2.6 K | Steward Partners Investment Advisory, Llc | 2024-12-31 | 2.5 K | Bank Of America Corp | 2024-12-31 | 1.1 K | Srs Capital Advisors Inc | 2024-12-31 | 1 K | Bfsg, Llc | 2024-12-31 | 1000 | Activest Wealth Management | 2024-12-31 | 1000 | Armistice Capital, Llc | 2024-12-31 | 2.2 M | Millennium Management Llc | 2024-12-31 | 633.8 K |
Enlivex Therapeutics Outstanding Bonds
Enlivex Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Enlivex Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Enlivex bonds can be classified according to their maturity, which is the date when Enlivex Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Enlivex Stock Analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.